Relay Therapeutics (RLAY) Depreciation & Amortization (CF) (2019 - 2026)
Relay Therapeutics (RLAY) reported Depreciation & Amortization (CF) of $504000.0 for Q1 2026, down 58.28% year-over-year from $1.2 million in Q1 2025, and down 15.86% on a QoQ basis from $599000.0 in Q4 2025.
Relay Therapeutics (RLAY) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $504000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 58.28% year-over-year to $504000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 45.94% YoY) and the FY2025 annual result came in at $3.6 million, down 34.9% from the prior year.
- Depreciation & Amortization (CF) declined to $504000.0 in Q1 2026 per RLAY's latest filing, from $599000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.4 million in Q1 2024 and bottomed at $504000.0 in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $1.2 million (2023), against an average of $1.1 million.
- The widest annual swing landed in 2023, when Depreciation & Amortization (CF) jumped 39.54%; it then sank 58.28% in 2026.
- Tracing RLAY's Depreciation & Amortization (CF) over 5 years: stood at $1.2 million in 2022, then grew by 17.92% to $1.4 million in 2023, then declined by 2.98% to $1.3 million in 2024, then sank by 55.1% to $599000.0 in 2025, then decreased by 15.86% to $504000.0 in 2026.
- Per Business Quant, the three latest RLAY Depreciation & Amortization (CF) figures stand at $504000.0 (Q1 2026), $599000.0 (Q4 2025), and $748000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Relay Therapeutics | 2.53 Bn | 2.53 Bn | - | 504,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 504,000.00 |
| Mar 31, 2026 | 504,000.00 |
| Dec 31, 2025 | 599,000.00 |
| Dec 31, 2025 | 599,000.00 |
| Sep 30, 2025 | 748,000.00 |
| Sep 30, 2025 | 748,000.00 |
| Jun 30, 2025 | 1.00 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.21 Mn |
| Mar 31, 2025 | 1.21 Mn |
| Dec 31, 2024 | 1.33 Mn |
| Dec 31, 2024 | 1.33 Mn |
| Sep 30, 2024 | 1.37 Mn |
| Sep 30, 2024 | 1.37 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Mar 31, 2024 | 1.40 Mn |
| Mar 31, 2024 | 1.40 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | 1.36 Mn |
| Sep 30, 2023 | 1.36 Mn |
| Jun 30, 2023 | 1.33 Mn |
| Jun 30, 2023 | 1.33 Mn |
| Mar 31, 2023 | 1.20 Mn |
| Mar 31, 2023 | 1.20 Mn |
| Dec 31, 2022 | 1.17 Mn |
| Dec 31, 2022 | 1.17 Mn |
| Sep 30, 2022 | 1.03 Mn |
| Sep 30, 2022 | 1.03 Mn |
| Jun 30, 2022 | 956,000.00 |
| Jun 30, 2022 | 956,000.00 |
| Mar 31, 2022 | 975,000.00 |
| Mar 31, 2022 | 975,000.00 |
| Dec 31, 2021 | 1.01 Mn |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 1.01 Mn |
| Sep 30, 2021 | 1.01 Mn |
| Jun 30, 2021 | 960,000.00 |
| Jun 30, 2021 | 960,000.00 |
| Mar 31, 2021 | 919,000.00 |
| Mar 31, 2021 | 919,000.00 |
| Dec 31, 2020 | 912,000.00 |
| Dec 31, 2020 | 912,000.00 |
| Sep 30, 2020 | 913,000.00 |
| Sep 30, 2020 | 913,000.00 |
| Jun 30, 2020 | 865,000.00 |
| Jun 30, 2020 | 865,000.00 |
| Mar 31, 2020 | 859,000.00 |
| Mar 31, 2020 | 859,000.00 |
| Dec 31, 2019 | 853,000.00 |
| Dec 31, 2019 | 853,000.00 |
| Sep 30, 2019 | 634,000.00 |
| Sep 30, 2019 | 634,000.00 |